FSHD patients sought for first clinical trial testing EPI-321

FSHD patients sought for first clinical trial testing EPI-321

Enrollment is now ongoing in a first-in-human trial testing EPI-321, an epigenetic therapy designed to address the root cause of facioscapulohumeral muscular dystrophy (FSHD), a disease type in which symptoms like muscle weakness typically become apparent by adulthood. The Phase 1/2 clinical trial (NCT06907875) is expected to enroll nine people with FSHD, ages 18-75, all of whom will receive a single infusion of EPI-321 at one of two doses. The …